ANL logo

Adlai Nortye Ltd.

ANL
Healthcare|Biotechnology|SG
$10.28
+0.60 (+6.20%)
DCF Value
$0.48
Tangible Book / Share
$13.49
Cash / Share
$14.56
Next Earnings Report
Mar 3, 2027
EPS est. -$0.15 · Revenue est. $3.5M
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Jul 20, 2026 (424B7). Possible dilution.

Upcoming Data Readouts (3)

Jul 2027
Est. completion
P1Advanced Solid Tumor (Phase 1)
An Initial Evaluation of AN8025 in Solid Tumors
NCT07639047n=91
Jan 2028
Est. completion
P1Solid Tumors (Phase 1)
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
NCT07252479n=118
Dec 2028
Est. completion
P1Solid Tumor (Phase I)
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
NCT07686445n=228

Recent Press Releases

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Oct 27, 2026 · GlobeNewsWire
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Oct 15, 2026 · GlobeNewsWire
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Sep 30, 2026 · GlobeNewsWire
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
Sep 8, 2026 · GlobeNewsWire
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Aug 14, 2026 · GlobeNewsWire

SEC Filings (45)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 28, 20266-KForeign issuer reportDocumentIndex
Oct 15, 20266-KForeign issuer reportDocumentIndex
Sep 30, 20266-KForeign issuer reportDocumentIndex
Sep 30, 20266-KForeign issuer reportDocumentIndex
Sep 15, 2026EFFECTDocumentIndex
Sep 11, 2026S-8 POSEmployee stock planDocumentIndex
Sep 11, 2026S-8 POSEmployee stock planDocumentIndex
Sep 11, 2026POS AMDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Aug 26, 20266-KForeign issuer reportDocumentIndex
Aug 19, 20266-KForeign issuer reportDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Jul 20, 2026424B7Offering prospectusDocumentIndex
Jul 17, 20266-KForeign issuer reportDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 28, 2026EFFECTDocumentIndex
Apr 24, 2026F-3/AShelf registrationDocumentIndex
Apr 23, 2026F-3/AShelf registrationDocumentIndex
Apr 16, 20266-KForeign issuer reportDocumentIndex
Apr 10, 202620-FAnnual report (foreign)DocumentIndex
Apr 1, 20266-KForeign issuer reportDocumentIndex
Mar 10, 2026F-3Shelf registrationDocumentIndex
Feb 12, 20266-KForeign issuer reportDocumentIndex
Feb 11, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 9, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 20266-KForeign issuer reportDocumentIndex
Jan 20, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Dec 29, 20256-KForeign issuer reportDocumentIndex
Dec 29, 20256-KForeign issuer reportDocumentIndex
Dec 3, 20256-KForeign issuer reportDocumentIndex
Oct 22, 20256-KForeign issuer reportDocumentIndex
Sep 16, 2025S-8Employee stock planDocumentIndex
Jul 9, 20256-KForeign issuer reportDocumentIndex
May 30, 20256-KForeign issuer reportDocumentIndex
May 12, 202520-F/AAnnual report (foreign)DocumentIndex